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Direct oral anticoagulants that target a single coagulation factor (such as factor Xa or
thrombin) have been developed in recent years in an attempt to address some of the
limitations of traditional anticoagulants. Rivaroxaban is an oral, direct factor Xa inhibitor
that inhibits free and clot-bound factor Xa and factor Xa in the prothrombinase complex.
Preclinical studies demonstrated a potent anticoagulant effect of rivaroxaban in plasma
as well as the ability of this agent to prevent and treat venous and arterial thrombosis
in animal models. These studies led to an extensive phase I clinical development
program that investigated the pharmacological properties of rivaroxaban in humans.
In these studies, rivaroxaban was shown to exhibit predictable pharmacokinetics and
pharmacodynamics and to have no clinically relevant interactions with many commonly
prescribed co-medications. The pharmacodynamic effects of rivaroxaban (for example,
inhibition of factor Xa and prolongation of prothrombin time) were closely correlated
with rivaroxaban concentrations in plasma. The encouraging findings from preclinical
and early clinical studies were expanded upon in large, randomized phase III studies,
which demonstrated the clinical efficacy and safety of rivaroxaban in a broad spectrum
of patients. This article provides an overview of the discovery and development of
rivaroxaban, describing the pharmacodynamic profile established in preclinical studies and
the optimal translation to clinical studies in healthy subjects and patient populations.
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INTRODUCTION
Anticoagulant drugs are routinely used for the prevention and
treatment of thromboembolic disorders. Although effective, tra-
ditional anticoagulant agents (which have a broad effect on mul-
tiple coagulation factors) are associated with several limitations.
For example, heparins require a parenteral route of administra-
tion, and unfractionated heparin and vitamin K antagonists have
significant variability in their pharmacodynamic responses, thus
requiring routine coagulation monitoring and dose adjustments
(McRae and Ginsberg, 2004; Ageno et al., 2012; Garcia et al.,
2012). These shortcomings have spurred the search for novel
agents that specifically target a single clotting factor within the
coagulation cascade, such as factor Xa or thrombin.
Factor X has long been known to have a key role in hemostasis,
and its activated form, factor Xa, has a significant function in the
blood coagulation pathway because it catalyzes the production of
thrombin, which leads to clot formation (Koller, 1960; Leadley,
2001). Activation of factor X to factor Xa occurs through both the
intrinsic and extrinsic pathways of the coagulation cascade. Factor
Xa initiates the final, common pathway that results in thrombin
activation via the prothrombinase complex (Figure 1). It has been
estimated that one molecule of factor Xa can catalyze the produc-
tion of∼1000molecules of thrombin because of the amplification
inherent in the coagulation cascade (Rand et al., 1996;Mann et al.,
2003; Kubitza and Haas, 2006; Perzborn et al., 2011); therefore,
effective thrombin inhibition requires sustained high levels of free
inhibitor under conditions of thrombin “burst.” These require-
ments are expected to be less stringent for factor Xa, because
factor X is present in plasma at much lower concentrations
compared with prothrombin (Brummel-Ziedins et al., 2012).
Factor Xa is, therefore, an attractive target for anticoagulant
agents.
Early studies of naturally occurring factor Xa inhibitors indi-
cated that targeting factor Xa could provide effective anticoagula-
tion (Dunwiddie et al., 1989; Nicolini et al., 1996). Further studies
with the synthetic indirect factor Xa inhibitor fondaparinux pro-
vided the proof of principle that selective inhibition of factor Xa
could provide clinically effective anticoagulation (Turpie et al.,
2002). Selective inhibition of factor Xa produces antithrombotic
effects by decreasing the generation of thrombin, thus dimin-
ishing thrombin-mediated activation of both coagulation and
platelets without affecting the activity of existing thrombin (Ieko
et al., 2004).
Among the novel, direct, oral factor Xa inhibitors that have
been developed in recent years, rivaroxaban was the first to gain
regulatory approval for clinical use (which occurred in 2008).
The pharmacodynamic effects of rivaroxaban were first shown
in preclinical studies, and were subsequently demonstrated in
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FIGURE 1 | The blood coagulation pathway.
early clinical studies in humans. The promising results from the
early phase of development were confirmed in large-scale phase
III studies, in which the efficacy and safety of rivaroxaban were
demonstrated. Rivaroxaban is now approved for clinical use for
the prevention and treatment of venous and arterial thromboem-
bolic disorders (Bayer Pharma AG, 2013). This article will provide
an overview of the discovery and development of rivaroxaban,
describing the pharmacodynamic profile established in preclinical
studies and the optimal translation to clinical studies in healthy
subjects and patient populations.
PRECLINICAL PHARMACODYNAMIC PROFILE
High-throughput screening of approximately 200,000 com-
pounds revealed several hits that selectively inhibited the cleavage
of a chromogenic substrate by human factor Xa. The subsequent
optimization program led to the identification of rivaroxaban
as the lead compound for further development because of its
high binding affinity to factor Xa, potency in vitro, and in vivo
antithrombotic activity, as well as its favorable oral bioavailability
(Perzborn et al., 2011).
The mode of action of rivaroxaban is the direct and spe-
cific competitive inhibition of factor Xa (inhibition constant [Ki]
0.4 ± 0.02 nM), with >10,000-fold selectivity for factor Xa over
other serine proteases (Perzborn et al., 2005). Unlike the indi-
rect factor Xa inhibitor fondaparinux, or low molecular weight
heparins and unfractionated heparin, which exert their actions
via antithrombin, rivaroxaban directly inhibits prothrombinase
(half maximal inhibitory concentration [IC50] 2.1 ± 0.40 nM).
In human plasma, rivaroxaban also inhibits the activity of clot-
bound factor Xa (IC50 75 nM) in a concentration-dependent
manner (Depasse et al., 2005).
In whole blood and platelet-rich human plasma, nanomolar
concentrations of rivaroxaban significantly prolonged the initi-
ation phase of thrombin generation (TG), significantly reduced
the rate of the propagation phase of coagulation after tissue factor
(TF) activation, and led to a reduction in endogenous thrombin
potential (ETP)—a measure of the activity of thrombin multi-
plied by the time for which it remains active (Gerotziafas et al.,
2007). Rivaroxaban reduced the ETP by 50% at a concentration
of 35 nM; TG was almost completely inhibited in platelet-rich
plasma at physiologically relevant concentrations (80–100 nM)
of rivaroxaban (Gerotziafas et al., 2007). In platelet-poor human
plasma, rivaroxaban prolonged prothrombin time (PT; assessed
using Neoplastin Plus® from Roche Diagnostics, Mannheim,
Germany) in a concentration-dependent manner; the assay con-
centration required to double the PT was ∼691 nM (Perzborn
et al., 2005).
The promising data on the pharmacodynamic effects of
rivaroxaban obtained in these coagulation tests were supported
by studies in animal models of venous and arterial thrombosis. In
a rat venous stasis model, PT and factor Xa activity were affected
slightly at the half maximal effective dose (ED50) of rivaroxa-
ban (1.8-fold increase and 32% inhibition, respectively) and, at a
dose leading to almost complete inhibition of thrombus forma-
tion (0.3mg/kg), rivaroxaban prolonged PT moderately (3.2 ±
0.5-fold) and inhibited factor Xa activity (65 ± 3%) (Perzborn
et al., 2005). In a rat arteriovenous shunt model, oral rivarox-
aban inhibited factor Xa activity by 74% and prolonged PT by
3.2-fold; in a rabbit arteriovenous shunt model, factor Xa activ-
ity was almost completely inhibited (92%) by oral rivaroxaban,
but PT was prolonged only slightly (1.2-fold), at the respec-
tive ED50 values (Perzborn et al., 2005). These pharmacody-
namic effects of rivaroxaban were mirrored by its antithrombotic
activity. Rivaroxaban reduced thrombus formation in a dose-
dependent manner after intravenous administration in the rat
venous stasis model, and after oral administration in the rat
and rabbit arteriovenous shunt models (Figure 2) (ED50 0.1, 5.0,
and 0.6mg/kg, respectively), providing the first demonstration
that rivaroxaban is effective in both arterial and venous throm-
bosis (Perzborn et al., 2005). In addition to prophylactic use,
results obtained in an experimental rabbit jugular vein thrombo-
sis model found that oral rivaroxaban (3.0mg/kg) significantly
reduced thrombus growth compared with oral control (36.9 ±
1.7% vs. 46.3 ± 1.3%; p < 0.05), demonstrating the potential
of rivaroxaban to treat established thrombi (Biemond et al.,
2007). No significant increase in bleeding time was observed at
antithrombotic-effective doses (Perzborn et al., 2005; Biemond
et al., 2007).
PHARMACODYNAMIC EFFECT IN CLINICAL STUDIES
PHASE I STUDIES
Results of single- and multiple-dose escalation studies in healthy
male subjects were consistent with those obtained in preclinical
studies, confirming the anticoagulation effects of rivaroxaban in
humans (Kubitza et al., 2005a,b). In the single-dose study, factor
Xa activity was inhibited in a dose-dependent manner, and up to
75% inhibition was achieved with a single 80mg dose of rivarox-
aban (Kubitza et al., 2005a). Maximal factor Xa inhibition with
suspension and tablet formulations was achieved after 45min
and 1–4 h, respectively (Kubitza et al., 2005a). Factor Xa activ-
ity was inhibited even at 24 h after administration at doses>5mg
(Kubitza et al., 2005a). Rivaroxaban prolonged the PT in a dose-
dependent manner (assessed using Neoplastin Plus® from Roche
Diagnostics, as in the preclinical studies). The inhibition of factor
Xa activity and prolongation of PT both correlated strongly with
plasma concentrations of rivaroxaban (r = 0.949 and r = 0.935,
respectively) (Kubitza et al., 2005a).
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After multiple dosing, maximal inhibition of factor Xa and
prolongation of PT did not show cumulative effects, illustrat-
ing predictable pharmacodynamics with repeated dosing (Kubitza
et al., 2005b).
In healthy male subjects, rivaroxaban (5 or 30mg) dose-
dependently inhibited TG in response to TF or collagen stimu-
lation in platelet-rich and platelet-poor plasma, suggesting effec-
tive inhibition of TG induced by the extrinsic and intrinsic
coagulation pathways (Graff et al., 2007, 2008). All parame-
ters of ETP [area under the plasma concentration–time curve
(AUC), peak, lag time] were significantly affected by rivarox-
aban 5 and 30mg doses, with the maximal effect achieved at
FIGURE 2 | (A) Reduction in thrombus formation and (B) prolongation of
prothrombin time with rivaroxaban in a rabbit arteriovenous shunt model.
Each value represents the mean ± SEM of six animals. ∗p < 0.05;
∗∗p < 0.01; ∗∗∗p < 0.001. Data published previously in the Journal of
Thrombosis and Haemostasis (Perzborn et al., 2005).
2 h (Graff et al., 2007, 2008). ETP peak (activated by collagen)
remained reduced by 40% at 24 h after administration of a 30mg
dose (Graff et al., 2007, 2008); this was the first evidence to sup-
port the concept of once-daily administration (Graff et al., 2007,
2008).
PHASE II AND III STUDIES
In phase II studies investigating rivaroxaban compared with
enoxaparin for the prevention of venous thromboembolism
(VTE) after hip or knee replacement surgery, rivaroxaban exhib-
ited predictable pharmacodynamics with both once- and twice-
daily dosing (Turpie et al., 2006; Eriksson et al., 2007a). As
was observed in phase I studies in healthy subjects, factor Xa
inhibition and PT prolongation correlated closely with rivarox-
aban plasma concentrations (Turpie et al., 2006; Eriksson et al.,
2007b). The correlation of PT prolongation with rivaroxaban
plasma concentration was also demonstrated in a phase II study,
ODIXa-DVT, which investigated the optimal dose of rivaroxa-
ban for the treatment of acute, proximal deep vein thrombosis
(Agnelli et al., 2007; Mueck et al., 2007). These data demon-
strated that the pharmacodynamic effects of rivaroxaban, as
shown for PT prolongation, were consistent between the pre-
clinical and clinical studies performed in healthy volunteers
and patients, when the same assay methods were used (e.g.,
Neoplastin Plus® from Roche Diagnostics for PT) (Table 1).
The consistent response among different patient populations and
Table 1 | Prolongation of PT in preclinical and clinical studies of
rivaroxaban.
Study Dose PT prolongation
(x-fold)
In vitro Platelet-poor human plasma
(Perzborn et al., 2005)
0.30 (µg/L) 2.0
Ex vivo Rat venous stasis model
(Perzborn et al., 2005)
0.1 (mg/kg)* 1.8
Rat arteriovenous shunt model
(Perzborn et al., 2005)
5.0 (mg/kg) 3.2
Rabbit arteriovenous shunt
model (Perzborn et al., 2005)
0.6 (mg/kg) 1.2
Rabbit jugular vein thrombosis
(Biemond et al., 2007)
3.0 (mg/kg)* 1.5
10.0 (mg/kg)* 1.8
Phase I Single-dose escalation study
in healthy subjects
(Kubitza et al., 2005a)
10mg 1.4
20mg 1.6
Phase II VTE prevention after major
orthopaedic surgery
(ODIXa-HIP)
(Eriksson et al., 2006)
10mg once
daily
1.4†
*After intravenous administration of rivaroxaban; †Data on file. PT, prothrombin
time; VTE, venous thromboembolism.
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the low-to-moderate inter-individual variability in the exposure–
PT relationship confirmed the predictable pharmacodynamics
of rivaroxaban (Mueck et al., 2008, 2011). Furthermore, the
observed pharmacodynamic effects in these early studies were
successfully translated into clinical efficacy, as demonstrated in a
number of large phase III studies in several thromboembolic indi-
cations, including the prevention of VTE after elective hip or knee
replacement surgery (Eriksson et al., 2008; Kakkar et al., 2008;
Lassen et al., 2008; Turpie et al., 2009), treatment of deep vein
thrombosis and pulmonary embolism and prevention of recur-
rent VTE (The EINSTEIN Investigators, 2010; The EINSTEIN–PE
Investigators, 2012), stroke prevention in patients with non-
valvular atrial fibrillation (Patel et al., 2011), and secondary
prevention in patients with acute coronary syndrome (Mega et al.,
2012). In these phase III studies, rivaroxaban was shown to be
superior or non-inferior to standard of care therapies (Table 2)
with a similar or improved safety profile (including major bleed-
ing events). The favorable benefit–risk profile of rivaroxaban was
also evident across patient subgroups.
PHARMACOKINETIC PROFILE AND CLINICAL RELEVANCE
Preclinical animal studies have shown rivaroxaban to have pre-
dictable pharmacokinetic properties. Rivaroxaban had a rapid
absorption, a moderate or high absolute bioavailability in rats
(57–66%) and dogs (60–86%), and dose-proportional plasma
concentrations with small variability between animals for the
tested dose-interval (1.0–10.0mg/kg in rats, 0.3–3.0mg/kg in
dogs) (Weinz et al., 2005). Rivaroxaban also showed a low
plasma clearance rate, a moderate volume of distribution, and
a short elimination half-life (Weinz et al., 2005). The tissue
affinity of rivaroxaban was moderate, with only small or no
retention observed; however, a species-dependent and fully
reversible high plasma protein binding was observed (Weinz et al.,
2005).
Rivaroxaban has a dual route of excretion through the bil-
iary/fecal and urinary pathways, with a recovery of total radioac-
tivity>91%being observed in all species tested. Urinary excretion
of radioactivity was 25 and 52%, and fecal excretion was 67 and
43% of the dose in rats and dogs, respectively (Weinz et al., 2005).
In humans, 36% of the administered dose was excreted renally
as unchanged drug, whereas 28% of the dose was excreted in the
feces (Weinz et al., 2009). Unchanged rivaroxaban was the main
component in human plasma, with no major or active circulating
metabolites present (Weinz et al., 2005, 2009; Bayer Pharma AG,
2013).
In phase I studies in healthymale subjects, rivaroxaban showed
rapid absorption after oral administration and reachedmaximum
plasma concentration (Cmax) within 4 h (Kubitza et al., 2005a,b).
Exposure to rivaroxaban, in terms of the AUC and Cmax, was dose
proportional for doses up to 10mg irrespective of food intake,
and dose proportional at all doses up to 30mg twice-daily if
administered with food (Kubitza et al., 2005a,b). No substantial
accumulation of rivaroxaban at steady state was detected in the
multiple-dose study (Kubitza et al., 2005b). The oral bioavailabil-
ity of rivaroxaban was high (80–100%) for the 10mg tablet dose,
regardless of food intake. Under fasting conditions, absorption of
a 20mg tablet decreased to 66%, but approached completeness
when the tablet was administered with food (Stampfuss et al.,
2013). The terminal half-life of rivaroxaban ranged between 5 and
9 h in healthy young subjects and between∼11 and 13 h in elderly
subjects (Kubitza et al., 2005a,b, 2008).
INTERACTIONS WITH DRUGS AFFECTING THE CYTOCHROME P450 3A4
AND P-GLYCOPROTEIN PATHWAYS
Rivaroxaban is metabolized via cytochrome P450 (CYP) 3A4,
CYP2J2, and CYP-independent mechanisms (Bayer Pharma AG,
2013; Mueck et al., 2013). Based on in vitro investigations, it
was shown that rivaroxaban is a substrate of the transporter pro-
teins P-glycoprotein (P-gp) and breast cancer resistance protein.
Consequently, drugs that affect CYP3A4, P-gp, or breast cancer
resistance protein are expected to influence the pharmacokinetics
of rivaroxaban (Gnoth et al., 2011; Mueck et al., 2013).
In phase I studies in healthy subjects, substrates of CYP3A4
or P-gp (such as the cardiac glycoside digoxin, the statin ator-
vastatin or the benzodiazepine midazolam) had no clinically
relevant effect on the plasma pharmacokinetics of rivaroxaban
(Kubitza et al., 2012b; Bayer Pharma AG, 2013; Mueck et al.,
2013). Substances strongly inhibiting only one pathway of elimi-
nation (such as the antibiotics clarithromycin and erythromycin
and the antifungal agent fluconazole) caused a modest increase in
rivaroxaban exposure (54, 34, and 42% increases, respectively),
but this did not result in clinically relevant increases in expo-
sure that would necessitate dose adaptations (Bayer Pharma AG,
2013; Mueck et al., 2013). However, rivaroxaban exposure was
found to be significantly increased when it was co-administered
with strong inhibitors of both P-gp and CYP3A4, such as keto-
conazole (158% increase in rivaroxaban exposure) and ritonavir
(153% increase in rivaroxaban exposure) (Bayer Pharma AG,
2013; Mueck et al., 2013). The use of rivaroxaban is, there-
fore, not recommended in patients receiving systemic azole-
antimycotics (such as ketoconazole, itraconazole, voriconazole,
and posaconazole) or HIV protease inhibitors (such as ritonavir)
(Bayer Pharma AG, 2013). Co-administration of the antibiotic
rifampicin, a strong CYP3A4 inducer, led to an approximately
50% decrease in the AUC of rivaroxaban. It is likely that other
strong CYP3A4 inducers (such as the anticonvulsants phenytoin,
carbamazepine, and phenobarbital, and the herbal supplement
St John’s wort) may lead to reduced plasma concentrations of
rivaroxaban (Bayer Pharma AG, 2013). These agents should,
therefore, be co-administered with rivaroxaban with caution
(Bayer Pharma AG, 2013).
EFFECT OF AGE, SEX, BODY WEIGHT, AND RENAL IMPAIRMENT ON
PHARMACOKINETIC PARAMETERS
Phase I clinical studies have investigated the effect of age
and sex on rivaroxaban pharmacokinetics. In healthy subjects
aged >75 years, there was an increase in rivaroxaban exposure
after the administration of a single 10mg dose, as indicated by
higher AUC values, compared with those observed in younger
subjects (18–45 years), without a significant alteration in Cmax
(Kubitza et al., 2013). The AUC values were, on average, 41%
greater than those observed in younger individuals (Kubitza et al.,
2013). These changes were the result of reduced rivaroxaban clear-
ance in elderly subjects, mainly owing to decreased renal function
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Table 2 | Clinical evaluation of rivaroxaban in phase III studies.
Study name Clinical setting Rivaroxaban dose
regimen
Comparator Efficacy outcome
RECORD1
(Eriksson et al., 2008)
Thromboprophylaxis in
patients undergoing total hip
replacement surgery
10mg od for 35
days post-surgery
Enoxaparin 40mg od
for 35 days
post-surgery
Rivaroxaban was significantly more
effective than enoxaparin for the
prevention of VTE after total hip
replacement surgery
RECORD2
(Kakkar et al., 2008)
Extended
thromboprophylaxis in
patients undergoing total hip
replacement surgery
10mg od for 31–39
days post-surgery
Enoxaparin 40mg od
for 10–14 days
post-surgery
Extended thromboprophylaxis with
rivaroxaban was significantly more
effective than short-term enoxaparin for
the prevention of VTE after total hip
replacement surgery
RECORD3
(Lassen et al., 2008)
Thromboprophylaxis after
total knee replacement
surgery
10mg od for 10–14
days post-surgery
Enoxaparin 40mg od
for 10–14 days
post-surgery
Rivaroxaban was superior to enoxaparin
for the prevention of VTE after total knee
replacement surgery
RECORD4
(Turpie et al., 2009)
Thromboprophylaxis after
total knee replacement
surgery
10mg od for 10–14
days post-surgery
Enoxaparin 30mg bid
for 10–14 days
post-surgery
Rivaroxaban was superior to enoxaparin
for the prevention of VTE after total knee
replacement surgery
EINSTEIN DVT
(The EINSTEIN
Investigators, 2010)
Treatment of confirmed acute
DVT without PE
15mg bid for 3
weeks followed by
20mg od for 3, 6, or
12 months
Enoxaparin 1mg/kg
overlapped and
followed by warfarin or
acenocoumarol (INR
2.0–3.0)
Rivaroxaban was non-inferior to standard
therapy for the treatment of DVT and
secondary prevention of VTE
EINSTEIN EXT
(The EINSTEIN
Investigators, 2010)
Treatment of confirmed
symptomatic DVT or PE after
6–12 months’ prior
anticoagulation
20mg od for 6 or 12
months
Placebo Rivaroxaban was superior to placebo for
the extended treatment of VTE
EINSTEIN PE
(The EINSTEIN–PE
Investigators, 2012)
Treatment of acute PE with or
without DVT
15mg bid for 3
weeks followed by
20mg od for 3, 6, or
12 months
Enoxaparin 1mg/kg
overlapped and
followed by warfarin or
acenocoumarol (INR
2.0–3.0)
Rivaroxaban was non-inferior to standard
therapy for the treatment of PE and
secondary prevention of VTE
ROCKET AF
(Patel et al., 2011)
Prevention of stroke or
systemic embolism in
patients with non-valvular AF
20mg od (15mg od
in patients with CrCl
30–49mL/min)
Warfarin [target INR of
2.5 (2.0–3.0)]
Rivaroxaban was non-inferior to warfarin
for the prevention of stroke or systemic
embolism in patients with non-valvular AF
ATLAS ACS 2 TIMI 51
(Mega et al., 2012)
Prevention of adverse
cardiovascular outcomes in
patients with a recent ACS
2.5mg or 5mg bid
for 13–31 months
Placebo At both doses, rivaroxaban reduced the
risk of adverse cardiovascular outcomes
after ACS alongside standard therapy
ACS, acute coronary syndrome; AF, atrial fibrillation; bid, twice daily; CrCl, creatinine clearance; DVT, deep vein thrombosis; INR, international normalized ratio;
od, once daily; PE, pulmonary embolism; VTE, venous thromboembolism.
(Kubitza et al., 2013). Sex had no significant influence on the
pharmacokinetics of rivaroxaban (Kubitza et al., 2013).
The influence of body weight on the pharmacokinetics of
rivaroxaban was investigated in healthy subjects weighing ≤50
and >120 kg, compared with those with a normal body weight
(70–80 kg) (Kubitza et al., 2007b). The Cmax of rivaroxaban
was unaffected in subjects >120 kg but was increased by 24%
in subjects weighing ≤50 kg, with no effect on AUC. This was
not considered clinically significant, suggesting that rivaroxa-
ban is unlikely to require dose adjustment for body weight in
adults (Kubitza et al., 2007b). Pharmacokinetic modeling has sug-
gested that dose adjustment may be required in pediatric patients
(Willmann et al., 2013); however, although studies are underway
(clinicaltrials.gov, NCT01145859), no clinical data are yet avail-
able on the use of rivaroxaban in this population, and rivaroxaban
is currently not recommended in patients aged <18 years (Bayer
Pharma AG, 2013).
Rivaroxaban clearance is decreased with increasing renal
impairment, leading to increased exposure. In subjects with mild
(creatinine clearance [CrCl], 50–79mL/min), moderate (CrCl,
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30–49mL/min), or severe (CrCl <30mL/min) impairment of
renal function, the AUCs of rivaroxaban were 44, 52, and 64%
higher, respectively, compared with healthy control subjects after
administration of a 10mg rivaroxaban dose (Kubitza et al., 2010).
The increase in AUC correlated inversely with CrCl (r = −0.45)
(Kubitza et al., 2010). Rivaroxaban Cmax was relatively unaffected,
indicating that the increase in AUC was caused by reduced clear-
ance and not by increased absorption (Kubitza et al., 2010). The
influence of renal function on rivaroxaban clearance is considered
to be moderate (Kubitza et al., 2010).
CLINICAL RELEVANCE OF PHARMACOKINETIC PARAMETERS
The consistent, predictable pharmacokinetics and pharmacody-
namics of rivaroxaban translated into predictable effects in the
clinical programs (Table 2). Analysis of data obtained across pre-
specified subgroups demonstrated consistent efficacy and safety
outcomes irrespective of age or renal function (Eriksson et al.,
2008; Kakkar et al., 2008; Lassen et al., 2008; Turpie et al.,
2009; The EINSTEIN Investigators, 2010; Patel et al., 2011; Mega
et al., 2012; The EINSTEIN–PE Investigators, 2012), including
in patients with atrial fibrillation with renal impairment who
received a reduced dose of rivaroxaban (15mg instead of 20mg)
for prevention of stroke and systemic embolism (Patel et al.,
2011). It should be noted that patients with CrCl <30mL/min
were excluded from all phase III studies; therefore, because lim-
ited data are available, rivaroxaban should be used with caution
in patients with severe renal impairment (CrCl 15–29mL/min)
(Bayer Pharma AG, 2013). The use of rivaroxaban is not recom-
mended in patients with CrCl <15mL/min (Bayer Pharma AG,
2013).
Data from the subgroup analyses further confirmed that
rivaroxaban dose adjustment is not required for age, sex, or body
weight (Eriksson et al., 2008; Kakkar et al., 2008; Lassen et al.,
2008; Turpie et al., 2009; The EINSTEIN Investigators, 2010; Patel
et al., 2011; Mega et al., 2012; The EINSTEIN–PE Investigators,
2012).
PHARMACODYNAMIC INTERACTIONS WITH DRUGS
AFFECTING HEMOSTASIS
Phase I studies in healthy male subjects evaluated the potential
for interactions with commonly prescribed drugs that influence
hemostasis, including non-steroidal anti-inflammatory drugs
such as naproxen, platelet aggregation inhibitors such as clopido-
grel, and the antiplatelet drug acetylsalicylic acid (ASA) (Kubitza
et al., 2006, 2007a, 2012a; Bayer Pharma AG, 2013).
The maximum inhibition of factor Xa and prolongation
of PT by rivaroxaban (administered as a single 15mg dose)
were unaffected in the presence of naproxen (500mg) (Kubitza
et al., 2007a). Rivaroxaban and naproxen given together signifi-
cantly increased bleeding time compared with rivaroxaban alone
(p = 0.017) (Kubitza et al., 2007a). However, this difference was
small compared with the effect of naproxen given alone (Kubitza
et al., 2007a).
Co-administration of clopidogrel (300mg loading dose fol-
lowed by 75mg maintenance dose) and rivaroxaban (15mg,
given on day 2) had no effect on rivaroxaban-mediated inhibi-
tion of factor Xa or prolongation of PT (Kubitza et al., 2012a).
Inhibition of adenosine 5′-diphosphate-stimulated platelet aggre-
gation by clopidogrel was not affected by rivaroxaban (Kubitza
et al., 2012a). Bleeding time was increased by clopidogrel,
and co-administration of rivaroxaban and clopidogrel further
increased bleeding time in a subset of subjects (Kubitza et al.,
2012a).
Acetylsalicylic acid (500mg loading dose followed by 100mg
maintenance dose) did not alter the effects of rivaroxaban (15mg)
on factor Xa activity or prolongation of PT (Kubitza et al., 2006).
Bleeding time was significantly prolonged with ASA; the combi-
nation of rivaroxaban and ASA prolonged bleeding time slightly
more than ASA alone (Kubitza et al., 2006).
These findings suggested a low potential for clinically rele-
vant interactions of rivaroxaban with these commonly prescribed
drugs; their use alongside rivaroxaban was investigated further in
phase III studies.
In the phase III studies for the prevention of VTE after elec-
tive hip or knee replacement surgery (the RECORD program;
Table 2), the concomitant use of ASA (no limit on dosage) and
other platelet inhibitors with rivaroxaban (10mg) was permit-
ted (Eriksson et al., 2008, 2012; Kakkar et al., 2008; Lassen et al.,
2008; Turpie et al., 2009). The relative rate ratios for any bleed-
ing events, or major or non-major clinically relevant bleeding
events, with different platelet inhibitors or ASA co-medication
use vs. non-use remained relatively constant and were similar
between the rivaroxaban and enoxaparin groups (Eriksson et al.,
2012). In the EINSTEIN program (Table 2), ASA (up to 100mg),
and clopidogrel (75mg per day), or both, were allowed if indi-
cated (The EINSTEIN Investigators, 2010; The EINSTEIN–PE
Investigators, 2012). Results obtained in a pooled analysis of
patients in the EINSTEIN DVT and EINSTEIN PE studies indi-
cated that co-administration of ASA with rivaroxaban increased
the risk of bleeding, with no statistically significant increase in
major bleeding, whereas use of non-steroidal anti-inflammatory
drugs increased the overall risk of bleeding and the risk of
major bleeding (Davidson et al., 2013). However, in general, an
increased risk of bleeding complications is expected when com-
bining an anticoagulant and antiplatelet agents, or other agents
that affect hemostasis. In the ATLAS ACS 2 TIMI 51 study,
increases in major bleeding (not related to coronary artery bypass
grafting) and intracranial hemorrhage were observed when a low
dose of rivaroxaban (2.5 or 5mg twice daily) was co-administered
with ASA and a thienopyridine (either clopidogrel or ticlopidine),
but no increases in fatal bleeding were observed (Mega et al.,
2012).
SUMMARY
Rivaroxaban is an oral, direct factor Xa inhibitor with high selec-
tivity for factor Xa, and which has been shown in clotting assays in
human plasma to effectively prolong PT, inhibit TG, and reduce
both collagen- and TF-induced ETP. The antithrombotic poten-
tial of rivaroxaban was first demonstrated in in vivo preclinical
studies in both arterial and venous thrombosis models, in which
the potential for the treatment of established thrombi was also
shown. These, together with data from initial (or early) clinical
studies, provided further support that factor Xa is a viable target
for anticoagulant therapy.
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The pharmacodynamic and pharmacokinetic profiles of
rivaroxaban seen in preclinical studies were further demonstrated
in phase I and II studies in humans. Here, the rapid onset
of action, short half-life, and plasma concentration-dependent
effects on coagulation were confirmed. Data obtained during
phase I and II studies also confirmed the predictability of rivarox-
aban effects across a range of patient populations. Alongside
the low potential for interacting with food or other drugs and
the wide therapeutic window, the predictable pharmacokinetic
and pharmacodynamic profile of rivaroxaban irrespective of age,
sex, or body weight obviates the need for routine coagulation
monitoring (in certain clinical situations laboratory testing may
be helpful, such as prior to urgent surgery), which opens the
possibility of offering fixed dosing to a broad range of patient
populations.
The promising preclinical data, first confirmed by results
of phase I studies, have been successfully translated into clini-
cally meaningful results in patients. The efficacy and safety of
rivaroxaban have been demonstrated in large-scale phase III
studies in multiple indications, with rivaroxaban having non-
inferior or superior efficacy to standards of care. In light of
these data, rivaroxaban has been approved for the prevention
or treatment of several thromboembolic indications. In order
to ensure responsible use in patients, prescribers should adhere
to the prescribing information for the respective indications.
There are patient populations in which rivaroxaban is contraindi-
cated or not recommended, including patients with severe renal
impairment with CrCl<15mL/min. With effective and safe anti-
coagulation coupled with oral, fixed dosing, rivaroxaban provides
an attractive alternative to traditional anticoagulants and has
the potential to simplify the management of thromboembolic
disorders.
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